Advances in understanding the role of P-gp in doxorubicin resistance: Molecular pathways, therapeutic strategies, and prospects
Year: 2021
Type: review
Abstract: P-glycoprotein (P-gp) is a drug efflux transporter that triggers doxorubicin (DOX) resistance. In this review, we highlight the molecular avenues regulating P-gp, such as Nrf2, HIF-1α, miRNAs, and long noncoding (lnc)RNAs, to reveal their participation in DOX resistance. These antitumor compounds and genetic tools synergistically reduce P-gp expression. Furthermore, ATP depletion impairs P-gp activity to enhance the antitumor activity of DOX. Nanoarchitectures, including liposomes, micelles, polymeric nanoparticles (NPs), and solid lipid nanocarriers, have been developed for the co-delivery of DOX with anticancer compounds and genes enhancing DOX cytotoxicity. Surface modification of nanocarriers, for instance with hyaluronic acid (HA), can promote selectivity toward cancer cells. We discuss these aspects with a focus on P-gp expression and activity.
Source: Drug Discovery Today
Institutions: Islamic Azad University, Science and Research Branch, Islamic Azad University Kazeron, University of Tehran, Islamic Azad University, Tehran, Sabancı Üniversitesi, Istinye University, Brigham and Women's Hospital, Harvard University, Dana-Farber/Harvard Cancer Center, Dana-Farber Brigham Cancer Center, University of the Basque Country, Singapore Eye Research Institute, Fundación Eduardo Anitua para la investigación biomédica
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,680
OpenAlex ID: W3204390294
